Hainan Hai Medicine wrote off the private placement of Changsha Hai Pharmaceuticals and terminated its investment in the Apricot Zexingfu Fund

Hainan Hai Pharmaceuticals (000566.SZ) announced that in order to focus on the main pharmaceutical industry and accelerate the disposal of non-main and non-dominant businesses, the Company decided to cancel the Changsha Hai Pharmaceutical Private Equity Partnership (Limited Partnership) ("Changsha Hai Pharmaceutical Private Equity") and to terminate its investment in Hangzhou Apricot Zexingfu Investment Management Partnership (Limited Partnership) ("Apricot Zexingfu Fund").
announcement shows that according to its focus on the development of the pharmaceutical industry business strategy needs, while in order to integrate and optimize the allocation of existing resources, improve the company's overall operating efficiency, reduce operating and management costs, the company has changsha hai medicine private placement liquidation and write-off.
company has received the "Notice of Granting Cancellation of Registration" (Yuelu) issued by the Market Supervision Bureau of Yuelu District of Changsha City, no. 30329, and has granted the private placement of Changsha Hai Medicine to cancel the registration.
as of the date of disclosure of this announcement, Changsha Hai Pharmaceutical Private Equity has been written off in accordance with the law.
the Provisions of the Shenzhen Stock Exchange's Stock Listing Rules and Articles of Association, the cancellation shall not need to be submitted to the Board of Directors of the Company and the General Meeting of Shareholders for consideration and approval.
in order to focus on the main pharmaceutical industry, while integrating the company's current actual operating situation, future development planning and other factors, the company decided to stop investing in the apricot Xingfu Fund.
source: Hainan Sea Medicine